Skip to main content
. Author manuscript; available in PMC: 2015 Jul 21.
Published in final edited form as: Phys Med Biol. 2014 Jun 24;59(14):3893–3905. doi: 10.1088/0031-9155/59/14/3893

Figure 4.

Figure 4

Feasibility of PRESAGE®-IV dosimetry: Each point on the plot corresponds to PRESAGE® 1.5% o-MeO-DEA formulation material in two forms (in optical cuvettes (ΔOD/cm) and PRESAGE®-IV dosimeters (ΔOD/0.4 cm)) irradiated to the same dose and the change in OD measured by spectrophotometry. The change in optical density of the dosimeters was multiplied by a factor of 1/0.4 cm to account for the difference in path length between the dosimeters and cuvettes.